[
  {
    "ts": null,
    "headline": "Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN",
    "summary": "NEW YORK, Feb. 18, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc.  .  Such investors are advised to contact Danielle...",
    "url": "https://finnhub.io/api/news?id=781a9b69225370612cbe836071ae4497c6f42364b716d98bb04e43d0e83428c5",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739902934,
      "headline": "Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN",
      "id": 132780616,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "NEW YORK, Feb. 18, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc.  .  Such investors are advised to contact Danielle...",
      "url": "https://finnhub.io/api/news?id=781a9b69225370612cbe836071ae4497c6f42364b716d98bb04e43d0e83428c5"
    }
  },
  {
    "ts": null,
    "headline": "FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea",
    "summary": "Teva Pharmaceutical Industries and partner Alvotech said the Food and Drug Administration agreed to review their AVTO6 treatment for eye disorders, which could compete with Regeneron Pharmaceuticals’ Eylea.",
    "url": "https://finnhub.io/api/news?id=ce9e5204fcd6b464e97c5c12fdb560bf97b2543068d030c7e56828ab31bc6b3a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739896075,
      "headline": "FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea",
      "id": 132819273,
      "image": "https://www.investopedia.com/thmb/_fzcBDUGzyt0jmJjbqzFccuV2Ts=/1500x0/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-2191898791-608600ef24ab42e1af0e5e78fe1e808d.jpg",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Teva Pharmaceutical Industries and partner Alvotech said the Food and Drug Administration agreed to review their AVTO6 treatment for eye disorders, which could compete with Regeneron Pharmaceuticals’ Eylea.",
      "url": "https://finnhub.io/api/news?id=ce9e5204fcd6b464e97c5c12fdb560bf97b2543068d030c7e56828ab31bc6b3a"
    }
  },
  {
    "ts": null,
    "headline": "SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority Tag",
    "summary": "The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for bullous pemphigoid by June 20, 2025.",
    "url": "https://finnhub.io/api/news?id=2ec98057da2efefeee778a7abca5148105192f0b757b821abb068185ad82d0f4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739882400,
      "headline": "SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority Tag",
      "id": 132819274,
      "image": "https://media.zenfs.com/en/zacks.com/5bd570f285e4b6d4e9b1a8c6dc8600e6",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for bullous pemphigoid by June 20, 2025.",
      "url": "https://finnhub.io/api/news?id=2ec98057da2efefeee778a7abca5148105192f0b757b821abb068185ad82d0f4"
    }
  },
  {
    "ts": null,
    "headline": "FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid",
    "summary": "As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues.",
    "url": "https://finnhub.io/api/news?id=d78c6027549d97df0f74ab9917c3cd2b97e3ee76d5831abf5e04606e9355dcf9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739881076,
      "headline": "FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid",
      "id": 132819276,
      "image": "https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/02/Picture5.jpg",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues.",
      "url": "https://finnhub.io/api/news?id=d78c6027549d97df0f74ab9917c3cd2b97e3ee76d5831abf5e04606e9355dcf9"
    }
  },
  {
    "ts": null,
    "headline": "American Century Focused Dynamic Growth Fund Q4 2024 Commentary",
    "summary": "The reelection of former President Donald Trump initially pleased investors who had worried about another protracted legal battle regarding the electionâs results.",
    "url": "https://finnhub.io/api/news?id=8d96f1a7ed9b70cba0740677fa661b9715838adf02954ff10196f42620bcc3bc",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739866200,
      "headline": "American Century Focused Dynamic Growth Fund Q4 2024 Commentary",
      "id": 132767142,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/165180102/image_165180102.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "The reelection of former President Donald Trump initially pleased investors who had worried about another protracted legal battle regarding the electionâs results.",
      "url": "https://finnhub.io/api/news?id=8d96f1a7ed9b70cba0740677fa661b9715838adf02954ff10196f42620bcc3bc"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron, Sanofi Get Speedy FDA Review of Dupixent in Bullous Pemphigoid",
    "summary": "Regeneron, Sanofi Get Speedy FDA Review of Dupixent in Bullous Pemphigoid",
    "url": "https://finnhub.io/api/news?id=8daf980f279be2d29c8f95def1cae13ec1f064b2605c6cb27bb812e108432f3d",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739859000,
      "headline": "Regeneron, Sanofi Get Speedy FDA Review of Dupixent in Bullous Pemphigoid",
      "id": 132773383,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron, Sanofi Get Speedy FDA Review of Dupixent in Bullous Pemphigoid",
      "url": "https://finnhub.io/api/news?id=8daf980f279be2d29c8f95def1cae13ec1f064b2605c6cb27bb812e108432f3d"
    }
  },
  {
    "ts": null,
    "headline": "Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)",
    "summary": "If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results demonstrating significant improvements in sustained disease remission with Dupixent compared to placebo BP is a chronic, debilitating and relapsing skin disease with underlying type 2 inflammation characterized by intense itch and blisters, reddening of the skin and painful lesions TARRYTOWN, N.Y. and PARIS,",
    "url": "https://finnhub.io/api/news?id=03cdfe7c448c465da25de59d86f7acfff1a67eded72b1281ee86e6db1fd0ac5e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739858340,
      "headline": "Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)",
      "id": 132819278,
      "image": "https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results demonstrating significant improvements in sustained disease remission with Dupixent compared to placebo BP is a chronic, debilitating and relapsing skin disease with underlying type 2 inflammation characterized by intense itch and blisters, reddening of the skin and painful lesions TARRYTOWN, N.Y. and PARIS,",
      "url": "https://finnhub.io/api/news?id=03cdfe7c448c465da25de59d86f7acfff1a67eded72b1281ee86e6db1fd0ac5e"
    }
  }
]